Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > why interview whit salzman
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(280)
•••
Comment by Dude51on Aug 13, 2021 7:12pm
258 Views
Post# 33705122

RE:why interview whit salzman

RE:why interview whit salzmanYou have to wonder, was interview with Andrew of any use? You can talk about the future and how great it's going to be all you want. What your not talking about is the elephant in the room and that is where are we with phase one? One answer is it's the TSXV and the lawyers fault. Something is fishy, wheretf is phase 1? Why not put out a news communication to that affect? Oh look at the share price, falling again. WTF Robert? We know Andrew is just a consultant so looks like the buck stops with you Robert. Why is it what you and Andrew have insinuated why is it not happening? It's not happening to your insinutated time frame. Phase 1 would be completely finished by end of year when we have no start date and share price falling again? Please give us an excuse we can verify.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities